Controlled trial of nimodipine in amyotrophic lateral sclerosis

Neuromuscular Disorders

Volumn 6, Issue 2, 1996, Pages 101-104

  Miller, Robert G ^a   Shepherd, Rodger ^b   Dao, Hung ^a   Khramstov, Andrei ^a   Mendoza, Michelle ^a   Graves, Jaretta ^c   Smith, Steven ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

Amytrophic lateral sclerosis; Calcium channel blockers; Clinical trial; Motor neuron disease; Nimodipine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; EXCITATORY AMINO ACID RECEPTOR; NIMODIPINE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CALCIUM TRANSPORT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FUNCTION; SYNCOPE; VERTIGO;

EID: 0029923440     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-8966(95)00024-0     Document Type: Article

References (14)

1. Constantakakis E, Plaitakis A. N-acetylaspartate and acetylaspartyl glutamate are altered in the spinal cord in ALS. Ann Neurol 1988; 24: 478.
2. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic aminoacids glutamate and aspartate are altered in the spinal cord and brain in ALS. Ann Neurol 1988; 24: 446-449.
3. Weiss J H, Choi D W. Slow non-NMDA receptor mediated neurotoxicity and ALS. In: Rowland LP, ed. ALS and other motor neuron disease. New York: Raven Press, 1991: 311-318.
4. MacDermott A B, Mayer M L, et al. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. Nature 1986; 321: 519-522.
5. Brooks, B R. El Escorial World Federation of Neurology criteria for the diagnosis of amytrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Group on Neuromuscular Diseases and the El Escorial Clinical limits of amytrophic lateral sclerosis workshop contributors. J Neurol Sci 1994; 12: 96-107.
6. Ringel S P, Murphy J R, Alderson M K, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-1322.
7. Andres P L, Hedlund W, Finison L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986; 36: 937-941.
8. Sharma K R, Mynhier M A, Miller R G. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993; 43: 527-532.
9. Mendell J R, Moxley R T, Gilder B, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320: 1592-1597.
10. Griggs R C, Moxley R T, Mendell J R, et al. Prednisone in Duchenne dystrophy. Arch Neurol 1991; 48: 383-388.
11. Choi D W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 23-634.
12. Weiss J H, Hartley D M, Koh J, et al. The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science 1990; 247: 1474-1477.
13. [++] influx into neurons by kainic acid. J Pharmacol Exp Ther 1989; 249: 184-193.
14. Smith R G, Hamilton S, Hoffman F, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992; 327: 1721-1728.